Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1971 1
1973 1
1975 2
1976 2
1977 2
1978 5
1979 4
1980 8
1981 9
1982 4
1983 8
1984 11
1985 4
1986 13
1987 13
1988 6
1989 7
1990 13
1991 14
1992 10
1993 11
1994 19
1995 23
1996 18
1997 26
1998 18
1999 15
2000 19
2001 18
2002 20
2003 25
2004 28
2005 29
2006 31
2007 32
2008 30
2009 36
2010 34
2011 39
2012 44
2013 39
2014 39
2015 48
2016 45
2017 41
2018 50
2019 52
2020 41
2021 35
2022 32
2023 33
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

991 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Benign neoplasm of hypopharynx"
Page 1
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment.
Marur S, Forastiere AA. Marur S, et al. Mayo Clin Proc. 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. Mayo Clin Proc. 2016. PMID: 26944243 Review.
The risk factors for development of cancers of the oral cavity, oropharynx, hypopharynx, and larynx include tobacco exposure and alcohol dependence, and infection with oncogenic viruses is associated with cancers developing in the nasopharynx, palatine, and lingual tonsils …
The risk factors for development of cancers of the oral cavity, oropharynx, hypopharynx, and larynx include tobacco exposure and alco …
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL. Bernier J, et al. Head Neck. 2005 Oct;27(10):843-50. doi: 10.1002/hed.20279. Head Neck. 2005. PMID: 16161069
METHODS: Both studies compared the addition of concomitant relatively high doses of cisplatin (on days 1, 22, and 43) to radiotherapy vs radiotherapy alone given after surgery in patients with high-risk cancers of the oral cavity, oropharynx, larynx, or hypopharynx. A comp …
METHODS: Both studies compared the addition of concomitant relatively high doses of cisplatin (on days 1, 22, and 43) to radiotherapy vs rad …
Cancer of the Larynx and Hypopharynx.
Echanique KA, Evans LK, Han AY, Chhetri DK, St John MA. Echanique KA, et al. Hematol Oncol Clin North Am. 2021 Oct;35(5):933-947. doi: 10.1016/j.hoc.2021.05.005. Epub 2021 Jul 14. Hematol Oncol Clin North Am. 2021. PMID: 34272102 Review.
The Radiation Therapy Oncology Group 91-11 trial and US Veterans Affairs trial revolutionized the way locally advanced laryngeal cancers are treated. ...
The Radiation Therapy Oncology Group 91-11 trial and US Veterans Affairs trial revolutionized the way locally advanced larynge …
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Bourhis J, et al. Future Oncol. 2022 May;18(14):1669-1678. doi: 10.2217/fon-2021-1634. Epub 2022 Feb 17. Future Oncol. 2022. PMID: 35172587 Free article.
Here, we describe the design of TrilynX (NCT04459715), a randomized, double-blind, phase III study. In total, 700 patients with unresected LA SCCHN will be randomized 1:1 to receive xevinapant or placebo plus standard-of-care CRT followed by xevinapant monotherapy o …
Here, we describe the design of TrilynX (NCT04459715), a randomized, double-blind, phase III study. In total, 700 patients with unres …
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, Docetaxel for Larynx Preservation.
Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Janoray G, et al. J Natl Cancer Inst. 2015 Dec 16;108(4):djv368. doi: 10.1093/jnci/djv368. Print 2016 Apr. J Natl Cancer Inst. 2015. PMID: 26681800 Clinical Trial.
METHODS: Operable patients with untreated stage III or IV larynx or hypopharynx invasive squamous cell carcinoma who required total laryngectomy were randomly assigned to three cycles of induction chemotherapy with either TPF or PF, followed by radiation therapy for …
METHODS: Operable patients with untreated stage III or IV larynx or hypopharynx invasive squamous cell carcinoma who required total l …
Treatment Options for Hypopharyngeal Cancer.
Eckel HE, Bradley PJ. Eckel HE, et al. Adv Otorhinolaryngol. 2019;83:47-53. doi: 10.1159/000492308. Epub 2019 Feb 12. Adv Otorhinolaryngol. 2019. PMID: 30943512 Review.
They also include considerations regarding potential delay between diagnosis and treatment, and between different treatment modalities within the frame of multimodal therapy. To date only one randomised trial comparing surgical versus non-surgical approaches has bee …
They also include considerations regarding potential delay between diagnosis and treatment, and between different treatment modalities withi …
Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas.
Wang K, Gui L, Lu H, He X, Li D, Liu C, Liu S, Wang X. Wang K, et al. Front Immunol. 2023 Jul 31;14:1189752. doi: 10.3389/fimmu.2023.1189752. eCollection 2023. Front Immunol. 2023. PMID: 37583698 Free PMC article. Clinical Trial.
BACKGROUND: This study aimed to explore the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinomas (LA-HNSCCs). METHODS: In this prospective, single-arm, single-cen …
BACKGROUND: This study aimed to explore the efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy in patien …
Comparison of two schedules of hypo-fractionated radiotherapy in locally advanced head-and-neck cancers.
Adlakha P, Maheshwari G, Dhanawat A, Sinwer R, Singhal M, Jakhar SL, Sharma N, Kumar HS. Adlakha P, et al. J Cancer Res Ther. 2022 Dec;18(Supplement):S151-S156. doi: 10.4103/jcrt.JCRT_1793_20. J Cancer Res Ther. 2022. PMID: 36510956 Free article. Clinical Trial.
MATERIALS AND METHODS: A total of 70 patients of LAHNC were randomized to receive palliative RT in two groups of 35 each. Group A received 30 Gy/10# over 2 weeks and Group B received 20 Gy/5# over 1 week. ...The most common sites were oropharynx (39%) followed by larynx (2 …
MATERIALS AND METHODS: A total of 70 patients of LAHNC were randomized to receive palliative RT in two groups of 35 each. Group A rec …
Efficacy and Quality-of-Life Following Involved Nodal Radiotherapy for Head and Neck Squamous Cell Carcinoma: The INRT-AIR Phase II Clinical Trial.
Sher DJ, Moon DH, Vo D, Wang J, Chen L, Dohopolski M, Hughes R, Sumer BD, Ahn C, Avkshtol V. Sher DJ, et al. Clin Cancer Res. 2023 Sep 1;29(17):3284-3291. doi: 10.1158/1078-0432.CCR-23-0334. Clin Cancer Res. 2023. PMID: 37363993 Clinical Trial.
PATIENTS AND METHODS: Patients with newly diagnosed HNSCC of the oropharynx, larynx, and hypopharynx were eligible for enrollment. Each LN was characterized as involved or suspicious based on radiologic criteria and an in-house artificial intelligence (AI)-based classifica …
PATIENTS AND METHODS: Patients with newly diagnosed HNSCC of the oropharynx, larynx, and hypopharynx were eligible for enrollment. Ea …
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Chan KK, Glenny AM, Weldon JC, Furness S, Worthington HV, Wakeford H. Chan KK, et al. Cochrane Database Syst Rev. 2015 Dec 1;2015(12):CD010341. doi: 10.1002/14651858.CD010341.pub2. Cochrane Database Syst Rev. 2015. PMID: 26625332 Free PMC article. Review.
We searched the US National Institutes of Health Trials Register (clinicaltrials.gov), the World Health Organization Clinical Trials Registry Platform, the American Society of Clinical Oncology conference abstracts and the Radiation Therapy Oncology Group clinica …
We searched the US National Institutes of Health Trials Register (clinicaltrials.gov), the World Health Organization Clinical Trials …
991 results